Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0007097 (carcinoma)
 152,788 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The steroid complexes of (plasma) corticosteroid-binding globulin can be distinguished from intracellular steroid-receptor complexes by agar electrophoresis at low temperature in neuraminidase-treated tissue extracts. With this method, the presence of progesterone receptor has been demonstrated in heavily plasma-protein-contaminated human uterus "cytosol", but not in human mammary carcinoma extracts. SHBG and "basic" receptors for estradiol and dihydrotestosterone in human uterus cytosol could also be assayed simultaneously.
 ...
PMID:Differentiation between steroid hormone receptors CBG and SHBG in human target organ extracts by a single-step assay. 17 88

The S-phase fraction (SPF), defined as the number of cells per hundred that showed evidence of nuclear DNA synthesis detectable by autoradiography after in vitro incubation with tritiated thymidine, was measured in 170 primary, invasive carcinomas of the breast. Assay for estrogen receptor was performed on tissue from 129 carcinomas, and 34 were also assayed for progesterone receptor. The concentration of estradiol-17 beta was measured in the serum of 69 patients. All carcinomas were analyzed for a variety of histologic features and were classified into morphologic types. SPF were lognormally distributed and were negatively correlated with the patient's age and presence of estrogen receptor, but not with presence of progesterone receptor, size of the carcinoma, number of axillary nodal metastases, or concentration of estradiol-17 beta in serum. The SPFs of lobular, mucinous, and tubular carcinomas were consistently low (geometric mean 1.2, range 0.05 to 3.55), and the SPFs of medullary and atypical medullary carcinomas were consistently high (geometric mean 14.0, range 7.77 to 20.2), whereas carcinomas of other types (not otherwise specified) had an intermediate geometric mean (4.7) and a broad range (0.09 to 25.4). The carcinomas that were not otherwise specified could be divided into three groups with different geometric mean SPFs by nuclear morphologic criteria (1.2 for minimal atypicality, 3.5 for moderate, and 7.9 for severe). Therefore it is possible to sort breast carcinomas histologically into groups with low, intermediate, and high SPF. Correlations between SPF, estrogen receptor content, and microscopic morphology indicate the existence of distinctive subpopulations of breast carcinoma that may have epidemiologic and therapeutic importance.
 ...
PMID:Subpopulations of breast carcinoma defined by S-phase fraction, morphology, and estrogen receptor content. 21 52

Steroid receptor assays in advanced or recurrent breast cancer are now recognized as a method for predicting therapeutic response to endocrine therapy. ER (estrogen receptor) and PgR (progesterone receptor) were measured by sucrose gradient centrifugation. Breast cancer, benign mammary tumors, and normal mammary tissue were examined. Following extensive laboratory procedures, several results were observed. The specific binding of ER was observed at the 8S as was the binding of PgR. 45% of human breast cancers were ER(+) and about 20% were PgR (+), with the positive rate of PgR lower than that of ER. All normal mammary tissues were ER (-) and with the benign mammary tumors, 1 of 10 fibroadenomas and 1 of 3 giant fibroadenomas was ER (+). Positive rates of ER and PgR were similar between premenopausal and postmenopausal females and across blood types A, B, and O. ER and PgR were negative in AB blood. The occurrence of ER in 10 cases of primary tumor and in metastatic or recurrent lesions was almost identical and binding sites were at almost the same level. Where both ER and PgR were measured in 39 cases, the 8 cases of PgR (+) showed ER (+) and there was a close relationship between the 2. With ER (+), papillotubular carcinomas tended to be lower than other histological types; in binding sites of ER, medullary tubular carcinoma occurred more frequently than schirrous carcinoma. Medullary tubular carcinoma occurred more often in the PgR. In 21 cases where the clinical response to endocrine therapy and the occurrence of ER were measured, 50% (6) of ER (+) and 25% of ER (+) or (-) displayed a response with 5 ER (-) cases showing no response. Endocrine therapy in 11 of 39 above mentioned cases was carried out with cases of ER (+) and PgR (+) responding better than those of ER (+) only. (Author's modified)
 ...
PMID:[Studies on estrogen and progesterone receptors in human breast cancer by sucrose gradient centrifugation (author's transl)]. 48 78

The presence or absence of steroid hormone receptors has been associated with predicting response to exogenous hormone therapy in breast tumors and in the treatment of metastases. This study was conducted to determine whether hormone receptors are present in cervical epithelium showing intraepithelial neoplasia. 18 biopsies of normal cervical epithelium were collected from hysterectomy patients with normal cervical cytology. 32 abnormal epithelium specimens were similarly obtained from patients with abnormal cervical cytology. An assay method using dextran-coated charcoal was performed to determine the values of estrogen and progesterone receptors in the cervical samples. Among those with normal epithelium, 67% were found to be estrogen receptor + compared to 77% of those with cervical intraepithelial neoplasia (CIN). Progesterone receptor sites were found in 61% of normal patients and 65% of CIN patients. The % of tumors (invasive cervical carcinoma) that are estrogen receptor positive have been found to vary from 0 to 25%. This study suggests a higher % of estrogen and progesterone receptor positivity in CIN than in invasive carcinoma with increasing concentration of receptors proportionate to the degree of dedifferentiation. Further studies should be done to determine whether hormone manipulation of cervical epithelium is of therapeutic and clinical value.
 ...
PMID:Hormone receptors in cervical intraepithelial neoplasia. 52 46

Oestrogen and progesterone receptors were determined in 48 primary tumors of invasive mammary carcinoma. 86% showed a positive oestrogen receptor binding, 53% were progesterone receptor positive. The binding capacity for oestradiol was 5-211 pmoles/g tissue protein, for progestin (R 5020) 7-146 pmoles. The question of the investigation was whether the content of determined receptors depends on endogenous oestradiol and progesterone concentrations. A clear dependence did not exist between the hormone level in the plasma, collected just before the excision of the tumor, and the amount of identifiable receptors in the tumor. On the contrary, in considering the quantities of endogenous hormones in the tissues, based on the plasma content of the tissue and the plasma hormone level, a correlation could be found. The content of identifiable receptors decreased with increasing amounts of endogenous hormones in the cytosol. It is postulated that rather the amount of endogenous hormones in the tissue than the plasma hormone level characterizes the degree of saturation of existing receptors by endogenous hormones. Apparently, the determined receptor concentrations at endogenous hormone values under 2 pmoles/g tissue protein reflect rather the true receptor content, whereas at higher values too low or false negative results should be reckoned with.
 ...
PMID:[The influence of endogenous hormones on the oestrogen and progesterone receptor determination in tissue of mammary carcinoma (author's transl)]. 58 Oct 55

[3H]Pregn-4-ene-3,20-dione ([3H]progesterone)-receptor complexes from human mammary carcinoma were found to be stabilized in the presence of glycerol. The dissociation rate constant was lowered and the equilibrium dissociation constant was decreased (KD=3 nM in the absence of glycerol and 1.1 nM in the presence of 30% glycerol), whereas no clear-cut effect on the association rate was observed and no change occurred in the concentration of binding sites. Cortisol was found to compete with [3H]progesterone only at concentrations higher than 1 muM. This made it possible to distinguish [3H]progesterone binding to the receptor from binding to corticosteroid-binding globulin. Synthetic progestins [6-chloro-17-acetoxypregna-4,6-diene-3,20-dione (chlromadinone acetate), 17alpha-ethinyl, 17-hydroxyestr-4-en-3-one (norethisterone), and 17,21-dimethyl-19-norpregna-4,9-diene-3,20-dione (R5020)] were found to have a high affinity for the receptor, whereas 5alpha-pregnane-3,20-dione had an affinity about one-half that of progesterone itself 5beta-Pregnane-3,20-dione, 17alpha-hydroxypregn-4-ene-3,20-dione (estradiol), 11beta,21-dihydroxy-pregn-4-ene-3,20-dione (corticosterone), estra-1,3,5(10)-triene-3,17beta-diol, and 17beta-hydroxyandrost-4-en-3-one (testosterone) were weak inhibitors of [3H]progesterone binding. Sedimentation on glycerol gradients showed different patterns in different tumors; i.e., [3H]progesterone specific binding having the characteristics of receptor was found either in the 8 S region, in the 4.5 S region, or in both. Activated progesterone-receptor complex from human mammary carcinoma cytosol was shown to bind to human DNA. An assay of the receptor based on these binding properties is described. This assay measures the total concentration of cytosol receptor since it makes possible the exchange of endogenous hormone for excess added [3H]progesterone. Of 55 biopsies examined by this method, 35 (64%) had a concentration of progesterone receptor-binding sites higher than 10 fmoles/mg protein. There was a positive correlation between the amounts of estrogen and progesterone receptors.
 ...
PMID:Characterization and assay of progesterone receptor in human mammary carcinoma. 83 70

Between 1977 and 1986, 879 patients with Stage I and II breast cancer underwent excisional biopsy, axillary dissection, and radiation. Median follow-up was 61 months (range 2-159 months). The patients were divided into seven groups based on histologic subtype: (a) 368 patients with both infiltrating and intraductal ductal carcinoma, (b) 389 infiltrating ductal carcinoma, (c) 41 infiltrating lobular carcinoma, (d) 23 combined infiltrating ductal and lobular carcinoma, (e) 28 medullary carcinoma, (f) 12 colloid carcinomas, and (g) 18 tubular carcinomas. Significant differences in clinical T status, pathologic nodal involvement, administration of chemotherapy, estrogen receptor positivity, progesterone receptor positivity, and age were observed between some histologic subgroups. Tubular and colloid carcinomas were more likely to present with T1 lesions, hormone receptor positivity, and node negative status than the other histologic subtypes. Most medullary carcinomas were hormone receptor negative and were younger than 50 years old. Infiltrating lobular carcinoma patients were more frequently lymph node negative, older, node negative, and estrogen receptor positive compared to the other groups (except for tubular and colloid patients). Differences in the administration of chemotherapy primarily reflected differences in lymph node involvement. Location of the tumor in the breast and menopausal status did not correlate with histologic subtype. There were no significant differences in 5-year actuarial overall survival, cause-specific survival, or relapse-free survival between the histologic categories. In addition, patterns of first failure were not significantly different among the histologic groups in terms of local-only first failure, any local component of first failure, regional-only first failure, or any regional component of first failure. There was, however, a difference among the seven groups in distant metastasis-only at first failure with invasive ductal carcinomas having the highest rate. Despite this difference, histologic subtype had no impact on survival. The site of in-breast failure relative to the location of the original tumor was not significantly different between groups. The histologic subtype of invasive breast cancer is not an independent risk factor in predicting survival or pattern of failure. Conservative surgery and radiation therapy is effective treatment of ductal, lobular, medullary, colloid, and tubular invasive breast cancer.
 ...
PMID:Outcome of conservative therapy for invasive breast cancer by histologic subtype. 132 87

Immunohistochemical analyses of estradiol, progesterone and progesterone receptor were carried out in human salivary gland and salivary adenoid cystic carcinoma. Immunoreactivity to estradiol and progesterone was found in cytoplasm of the cells of the excretory duct system within normal salivary glands, whereas the progesterone receptor was restricted to nuclei of the cells where both sex steroids were positive. In addition, we demonstrated the presence of both sex steroids and the receptor for progesterone in salivary adenoid cystic carcinomas. These data indicate that the human salivary gland is one of the target tissues of estrogen. This also suggests the good possibility that tumors which express progesterone receptors will respond to endocrine therapy.
 ...
PMID:Immunohistochemical localization of estradiol, progesterone, and progesterone receptor in human salivary glands and salivary adenoid cystic carcinomas. 132

As compared with the lymphatic system, the mononuclear phagocyte system (MPS) represents the older defense system in the course of evolution. Organisms with defective or with no lymphocytic function are able to live for a certain time while metazoa cannot develop and exist without cells capable of phagocytosis. It is known that up to 80% of the mass of malignant experimental tumors may consist of macrophages. The biological relevance of these tumor-associated macrophages (TAM), however, is contested to date. Besides well-known tasks in specific and non-specific defense, the cells of the MPS possess nutritive functions. The different functions of TAM have been essentially examined in animal experiments in vivo and in vitro up to now. These studies have shown, e.g., that TAM of different phenotypes to some extent are assigned to different functions and that each tumor or tumor cell line has a specific TAM pattern. The available number of monoclonal antibodies (MAB) able to recognize different groups of human macrophages has only increased in the recent past. This also provided evidence of the phenotypic heterogeneity of macrophages in the human system. On the other hand, there is little knowledge to date of the possible biological cause of the presence of numerous macrophages also in the stroma of malignant tumors in man and on the functional relevance of particular macrophage phenotypes. In the present studies, the phenotypic pattern of tumor-associated cells was examined by immunohistochemistry in the model of human mammary carcinoma, using 18 monoclonal antibodies (Ki-M1-8, Leu-M1-3, Leu-M5, EBM11, CD1, anti-transferrin receptor [TFR], anti-MHC I, anti-MHC II or anti HLA-DR) and one polyclonal antibody (anti protein-S100). The first part of the study contains a semiquantitative evaluation of 216 cases of mammary carcinoma. The analytical results are correlated with established prognostic factors available in the case of malignant tumors in general and in that of mammary carcinomas in particular (age, menopausal status of patients, axillary lymph node and estrogen/progesterone receptor status, size of tumor, tumor type according to WHO, degree of malignancy according to histopathological and nuclear grading). As tumor parameters of absolute biological relevance, proliferating activity (Ki67) and MHC phenotype of tumor cells and amount or types of tumor-associated lymphocytes (TAL) are examined in order to analyze their correlation with prognostic factors and their importance in the tumor-macrophage system.(ABSTRACT TRUNCATED AT 400 WORDS)
 ...
PMID:[Human mammary carcinoma. A model for the relationship between tumor proliferation, tumor-associate macrophages, and prognostic factors]. 132 68

c-myc, c-erbB-2, and Ki-67 expression was examined by immunohistochemistry in 11 normal breast tissues and 42 invasive and 14 noninvasive breast carcinomas. The c-myc product was detected in all breast carcinoma specimens and in 7 of 11 normal breast tissues. Invasive tumors stained more frequently with the anti-myc monoclonal antibody than did noninvasive tumors, while the level of expression in normal breast tissue was much less than that in breast cancer. Membrane staining of the c-erbB-2 protein was demonstrated in 29% (4 of 14) of noninvasive ductal carcinomas and in 45% (19 of 42) of invasive breast carcinomas. None of the 11 normal breast tissue samples was positive. The mean value of Ki-67-positive cells was 0.91 +/- 0.31% for normal breast tissue, 4.57 +/- 1.36% for noninvasive ductal carcinoma, and 12.76 +/- 2.18% for invasive breast cancer. In 42 invasive breast carcinomas, the expression of c-myc, c-erbB-2, and Ki-67 proliferation marker were compared with lymph node status, estrogen receptor status, progesterone receptor status, and age of patients at diagnosis. c-erbB-2 overexpression and Ki-67 overexpression were identified as the only factors associated with lymph node status. We concluded that they might be additional prognostic factors for breast carcinoma.
 ...
PMID:c-myc, c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma. 134 67


1 2 3 4 5 6 7 8 9 10 Next >>